{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:36:05Z","timestamp":1785796565415,"version":"3.56.0"},"reference-count":176,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["JP 20K09824"],"award-info":[{"award-number":["JP 20K09824"]}]},{"name":"JSPS KAKENHI","award":["22FC0201"],"award-info":[{"award-number":["22FC0201"]}]},{"name":"JSPS KAKENHI","award":["23fk0108671h0001"],"award-info":[{"award-number":["23fk0108671h0001"]}]},{"name":"JSPS KAKENHI","award":["23fk0108672h0001"],"award-info":[{"award-number":["23fk0108672h0001"]}]},{"name":"Grant on Rare and Intractable Diseases from the Ministry of Health, Labor, and Welfare of Japan","award":["JP 20K09824"],"award-info":[{"award-number":["JP 20K09824"]}]},{"name":"Grant on Rare and Intractable Diseases from the Ministry of Health, Labor, and Welfare of Japan","award":["22FC0201"],"award-info":[{"award-number":["22FC0201"]}]},{"name":"Grant on Rare and Intractable Diseases from the Ministry of Health, Labor, and Welfare of Japan","award":["23fk0108671h0001"],"award-info":[{"award-number":["23fk0108671h0001"]}]},{"name":"Grant on Rare and Intractable Diseases from the Ministry of Health, Labor, and Welfare of Japan","award":["23fk0108672h0001"],"award-info":[{"award-number":["23fk0108672h0001"]}]},{"name":"Research Program on Emerging and Re-emerging Infectious Diseases grant from the Japan Agency for Medical Research and Development, AMED","award":["JP 20K09824"],"award-info":[{"award-number":["JP 20K09824"]}]},{"name":"Research Program on Emerging and Re-emerging Infectious Diseases grant from the Japan Agency for Medical Research and Development, AMED","award":["22FC0201"],"award-info":[{"award-number":["22FC0201"]}]},{"name":"Research Program on Emerging and Re-emerging Infectious Diseases grant from the Japan Agency for Medical Research and Development, AMED","award":["23fk0108671h0001"],"award-info":[{"award-number":["23fk0108671h0001"]}]},{"name":"Research Program on Emerging and Re-emerging Infectious Diseases grant from the Japan Agency for Medical Research and Development, AMED","award":["23fk0108672h0001"],"award-info":[{"award-number":["23fk0108672h0001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>Background: Monoclonal antibodies (mAbs) have demonstrated substantial potential in the treatment of intraocular diseases. This review aimed to comprehensively evaluate the applications, efficacy, and safety of mAbs in the management of intraocular conditions. Methods: A comprehensive literature search was conducted in major medical databases through July 2024. Relevant studies on monoclonal antibodies for intraocular diseases were included. Two independent researchers screened the literature, extracted data, and assessed study quality. Cost-effectiveness analyses were also reviewed. Results: Anti-vascular endothelial growth factor (VEGF) antibodies, such as bevacizumab, ranibizumab, and aflibercept, showed significant therapeutic effects in neovascular age-related macular degeneration (NVAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Tumor necrosis factor-alpha (TNF-\u03b1) inhibitors demonstrated promising results in treating noninfectious uveitis. Complement system-targeted therapies like pegcetacoplan offered new options for geographic atrophy. Anti-VEGF antibodies showed potential in managing retinopathy of prematurity (ROP). However, challenges persist, including high costs, potential drug resistance, and limited long-term safety data in certain scenarios. Conclusions: Monoclonal antibodies are vital for treating intraocular diseases, but continuous innovation and rigorous clinical evaluation are essential. Future research should focus on developing novel delivery systems, exploring combination therapies, conducting long-term follow-up studies, and investigating personalized treatment strategies to provide safer, more effective, and cost-effective therapeutic solutions.<\/jats:p>","DOI":"10.3390\/antib13040086","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T08:54:27Z","timestamp":1728636867000},"page":"86","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Ophthalmic Use of Targeted Biologics in the Management of Intraocular Diseases: Current and Emerging Therapies"],"prefix":"10.3390","volume":"13","author":[{"given":"Yuan","family":"Zong","sequence":"first","affiliation":[{"name":"Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Miyagaki","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3124-1101","authenticated-orcid":false,"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1359-8198","authenticated-orcid":false,"given":"Yaru","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Ohno-Matsui","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koju","family":"Kamoi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Zahavi, D., and Weiner, L. (2020). Monoclonal Antibodies in Cancer Therapy. Antibodies, 9.","DOI":"10.3390\/antib9030034"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Milstein","year":"1975","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/APO.0000000000000371","article-title":"Biologic Drugs for the Treatment of Noninfectious Uveitis","volume":"10","author":"Ferreira","year":"2021","journal-title":"Asia-Pac. J. Ophthalmol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2337\/diacare.26.9.2653","article-title":"Diabetic retinopathy and diabetic macular edema: Pathophysiology, screening, and novel therapies","volume":"26","author":"Ciulla","year":"2003","journal-title":"Diabetes Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e248383","DOI":"10.1001\/jamanetworkopen.2024.8383","article-title":"Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity: Two-Year Efficacy and Safety Outcomes in the Nonrandomized Controlled Trial FIREFLEYE next","volume":"7","author":"Stahl","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s10238-022-00954-6","article-title":"Pathogenesis and current therapies for non-infectiousnoninfectious uveitis","volume":"23","author":"Wu","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Leclercq, M., Desbois, A.-C., Domont, F., Maalouf, G., Touhami, S., Cacoub, P., Bodaghi, B., and Saadoun, D. (2020). Biotherapies in Uveitis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113599"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ajo.2006.06.068","article-title":"Vascular Endothelial Growth Factor Is a Critical Stimulus for Diabetic Macular Edema","volume":"142","author":"Nguyen","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2337\/dc10-0493","article-title":"Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study","volume":"33","author":"Massin","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in Patients with Active Noninfectious Uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.ophtha.2020.10.036","article-title":"Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis","volume":"128","author":"Suhler","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Uchida, M., Kamoi, K., Ando, N., Wei, C., Karube, H., and Ohno-Matsui, K. (2019). Safety of Infliximab for the Eye Under Human T-Cell Leukemia Virus Type 1 Infectious Conditions in vitro. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.02148"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Busto-Iglesias, M., Rodr\u00edguez-Mart\u00ednez, L., Rodr\u00edguez-Fern\u00e1ndez, C.A., Gonz\u00e1lez-L\u00f3pez, J., Gonz\u00e1lez-Barcia, M., de Domingo, B., Rodr\u00edguez-Rodr\u00edguez, L., Fern\u00e1ndez-Ferreiro, A., and Mondelo-Garc\u00eda, C. (2023). Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-InfectiousNoninfectious Uveitis Treatment: A Review. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030766"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Yang, M., Kamoi, K., Zong, Y., Zhang, J., Zou, Y., and Ohno-Matsui, K. (2024). Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063229"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Zong, Y., Kamoi, K., Ando, N., Kurozumi-Karube, H., and Ohno-Matsui, K. (2022). Mechanism of Secondary Glaucoma Development in HTLV-1 Uveitis. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.738742"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kamoi, K. (2020). HTLV-1 in Ophthalmology. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.00388"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kitaguchi-Iwakiri, Y., Kamoi, K., Takase, H., Okubo, Y., and Ohno-Matsui, K. (2022). Long-term incidence of posterior capsular opacification in patients with non-infectiousnoninfectious uveitis. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-08325-7"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","article-title":"Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals of Care for UveitiS (FOCUS) Initiative","volume":"125","author":"Dick","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.preteyeres.2004.06.005","article-title":"The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU)","volume":"23","author":"Dick","year":"2004","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_23","first-page":"301","article-title":"Anti-TNF therapy in the management of ocular attacks in an elderly patient with long-standing Beh\u00e7et\u2019s disease","volume":"9","author":"Karube","year":"2016","journal-title":"Int. Med. Case Rep. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000055677","article-title":"Aqueous Humor and Serum Tumor Necrosis Factor-\u03b1 in Clinical Uveitis","volume":"33","author":"Omar","year":"2001","journal-title":"Ophthalmic Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/2008-322X.156110","article-title":"Aqueous Humor Levels of Different Interleukins 1-\u03b2, 2, 6 and 10, Tumor Necrosis Factor-\u03b1 and Vascular Endothelial Growth Factor in Uveitis Treated with Adalimumab","volume":"10","year":"2015","journal-title":"J. Ophthalmic Vis. Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Leal, I., Rodrigues, F.B., Sousa, D.C., Duarte, G.S., Rom\u00e3o, V.C., Marques-Neves, C., Costa, J., and Fonseca, J.E. (2019). Anti-TNF Drugs for Chronic Uveitis in Adults\u2014A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front. Med., 6.","DOI":"10.3389\/fmed.2019.00104"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Kurozumi-Karube, H., Kamoi, K., Ando, N., Uchida, M., Hamaguchi, I., and Ohno-Matsui, K. (2020). In vitro Evaluation of the Safety of Adalimumab for the Eye Under HTLV-1 Infection Status: A Preliminary Study. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.522579"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: A comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/25785826.2019.1642080","article-title":"The effectiveness of adalimumab treatment for non-infectiousnoninfectious uveitis","volume":"42","author":"Hasegawa","year":"2019","journal-title":"Immunol. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectiousnoninfectious uveitis controlled by corticosteroids (VISUAL II): A multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III","volume":"125","author":"Suhler","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.2147\/DDDT.S160431","article-title":"Efficacy and safety of adalimumab in the treatment of non-infectiousnoninfectious uveitis: A meta-analysis and systematic review","volume":"12","author":"Ming","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight-threatening panuveitis in Behcet\u2019s disease","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ophtha.2013.07.019","article-title":"Infliximab for the Treatment of Refractory Noninfectious Uveitis: A Study of 88 Patients with Long-term Follow-up","volume":"121","author":"Kruh","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.2147\/OPTH.S322445","article-title":"Biological Therapy in Noninfectious Pediatric Uveitis: A Systematic Review","volume":"15","author":"Norcia","year":"2021","journal-title":"Clin. Ophthalmol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Horiguchi, N., Kamoi, K., Horie, S., Iwasaki, Y., Kurozumi-Karube, H., Takase, H., and Ohno-Matsui, K. (2020). A 10-year follow-up of infliximab monotherapy for refractory uveitis in Beh\u00e7et\u2019s syndrome. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-78718-z"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Takeuchi, M., Usui, Y., Namba, K., Keino, H., Takeuchi, M., Takase, H., Kamoi, K., Hase, K., Ito, T., and Nakai, K. (2023). Ten-year follow-up of infliximab treatment for uveitis in Beh\u00e7et disease patients: A multicenter retrospective study. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1095423"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/art.39667","article-title":"Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study from the French Uveitis Network","volume":"68","author":"Vallet","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Valenzuela, R.A., Flores, I., Urrutia, B., Fuentes, F., Sabat, P.E., Llanos, C., Cuitino, L., and Urzua, C.A. (2020). New Pharmacological Strategies for the Treatment of Non-InfectiousNoninfectious Uveitis. A Minireview. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00655"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/rheumatology\/keq366","article-title":"A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Beh\u00e7et\u2019s disease: A comparative 4-week study","volume":"50","author":"Markomichelakis","year":"2010","journal-title":"Rheumatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/acr.20404","article-title":"Prevention of flare recurrences in childhood-refractory chronic uveitis: An open-label comparative study of adalimumab versus infliximab","volume":"63","author":"Simonini","year":"2011","journal-title":"Arthritis Care Res."},{"key":"ref_42","first-page":"864","article-title":"Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: A retrospective study of three cases from a single centre and literature review","volume":"32","author":"Blanco","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"105","DOI":"10.55563\/clinexprheumatol\/j9ysbm","article-title":"Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy","volume":"39","author":"Veroz","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/14397595.2017.1285857","article-title":"Certolizumab Pegol treatment in Behcet\u2019s disease with different organ involvement: A multicenter retrospective observational study","volume":"27","author":"Lopalco","year":"2017","journal-title":"Mod. Rheumatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/rheumatology\/ken489","article-title":"Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis","volume":"48","author":"Yoshimura","year":"2009","journal-title":"Rheumatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/cei.12295","article-title":"Interleukin-6 blockade in ocular inflammatory diseases","volume":"176","author":"Mesquida","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"112460","DOI":"10.1016\/j.intimp.2024.112460","article-title":"Evaluating tocilizumab safety and immunomodulatory effects under ocular HTLV-1 infection in vitro","volume":"137","author":"Zhang","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ajo.2017.08.019","article-title":"Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis","volume":"183","author":"Sepah","year":"2017","journal-title":"Am. J. Ophthalmol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/art.39940","article-title":"Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients","volume":"69","author":"Calvo","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/09273948.2017.1355471","article-title":"Tocilizumab for the Treatment of Beh\u00e7et Uveitis that Failed Interferon Alpha and Anti-Tumor Necrosis Factor-Alpha Therapy","volume":"26","author":"Oray","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Zhu, L., Chen, B., and Su, W. (2021). A Review of the Various Roles and Participation Levels of B-Cells in Non-InfectiousNoninfectious Uveitis. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.676046"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"107901","DOI":"10.1016\/j.exer.2019.107901","article-title":"Features of ectopic lymphoid-like structures in human uveitis","volume":"191","author":"Epps","year":"2020","journal-title":"Exp. Eye Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12348-021-00252-4","article-title":"Rituximab for non-infectiousnoninfectious Uveitis and Scleritis","volume":"11","author":"Ng","year":"2021","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1080\/09273948.2020.1820531","article-title":"Efficacy of B Cell Depletion Therapy with Rituximab in Refractory Chronic Recurrent Uveitis Associated with Vogt-Koyanagi-Harada Disease","volume":"30","author":"Dheyab","year":"2022","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1080\/09273948.2021.1880604","article-title":"Efficacy of Rituximab Treatment in Vogt-Koyanagi-Harada Disease Poorly Controlled by Traditional Immunosuppressive Treatment","volume":"30","author":"Bolletta","year":"2022","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4103\/0301-4738.194339","article-title":"Roles of interleukin-17 in uveitis","volume":"64","author":"Guedes","year":"2016","journal-title":"Indian J. Ophthalmol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.ophtha.2018.05.014","article-title":"Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis","volume":"125","author":"Pepple","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e12527","DOI":"10.1111\/dth.12527","article-title":"Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis","volume":"30","author":"Mugheddu","year":"2017","journal-title":"Dermatol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/ecco-jcc\/jjz167","article-title":"Two Cases of Successful Ustekinumab Treatment for Non-infectiousNoninfectious Uveitis Associated with Crohn\u2019s Disease","volume":"14","author":"Chateau","year":"2019","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejpb.2015.02.020","article-title":"Antibody therapies and their challenges in the treatment of age-related macular degeneration","volume":"95","author":"Volz","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"8374647","DOI":"10.1155\/2018\/8374647","article-title":"Age-Related Macular Degeneration: New Paradigms for Treatment and Management of AMD","volume":"2018","author":"Zenteno","year":"2018","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_64","unstructured":"National Eye Institute (2019). Age-Related Macular Degeneration (AMD) Data and Statistics."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1097\/IAE.0b013e318271f265","article-title":"Current knowledge and trends in age-related macular degeneration: Today\u2019s and Future Treatments","volume":"33","author":"Oliver","year":"2013","journal-title":"Retina"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Zong, Y., Kamoi, K., Kurozumi-Karube, H., Zhang, J., Yang, M., and Ohno-Matsui, K. (2023). Safety of intraocular anti-VEGF antibody treatment under in vitro HTLV-1 infection. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1089286"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Song, D., Liu, P., Shang, K., and Ma, Y. (2022). Application and mechanism of anti-VEGF drugs in age-related macular degeneration. Front. Bioeng. Biotechnol., 10.","DOI":"10.3389\/fbioe.2022.943915"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"786870","DOI":"10.1155\/2012\/786870","article-title":"Anti-VEGF Treatment Strategies for Wet AMD","volume":"2012","author":"Kovach","year":"2012","journal-title":"J. Ophthalmol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2147\/JEP.S259298","article-title":"Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration","volume":"13","author":"Kaiser","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Wallsh, J.O., and Gallemore, R.P. (2021). Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options. Cells, 10.","DOI":"10.3390\/cells10051049"},{"key":"ref_71","first-page":"2311","article-title":"Profile of conbercept in the treatment of neovascular age-related macular degeneration","volume":"9","author":"Lu","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/14712598.2021.1915278","article-title":"Brolucizumab: A novel anti-VEGF humanized single-chain antibody fragment for treating w-AMD","volume":"21","author":"Traverso","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1167\/iovs.12-10260","article-title":"Pharmacokinetics of Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration: A Population Approach","volume":"54","author":"Xu","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"37","DOI":"10.21037\/aes-21-41","article-title":"Molecular structure, pharmacokinetics and clinical evidence of brolucizumab: A narrative review","volume":"6","author":"Pignatelli","year":"2021","journal-title":"Ann. Eye Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.2147\/DDDT.S427416","article-title":"Faricimab: Transforming the Future of Macular Diseases Treatment\u2014A Comprehensive Review of Clinical Studies","volume":"17","author":"Panos","year":"2023","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/IAE.0000000000002566","article-title":"Pharmacokinetic study of intravitreal aflibercept in humans with neovascular age-related macular degeneration","volume":"40","author":"Do","year":"2020","journal-title":"Retina"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ajo.2012.03.047","article-title":"Intraocular Pharmacokinetics of Ranibizumab Following a Single Intravitreal Injection in Humans","volume":"154","author":"Krohne","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00417-013-2495-0","article-title":"Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes","volume":"252","author":"Moisseiev","year":"2014","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","article-title":"Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study","volume":"123","author":"Holz","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","article-title":"Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR","volume":"37","author":"Ohji","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","article-title":"Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients with Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial","volume":"141","author":"Wykoff","year":"2023","journal-title":"JAMA Ophthalmol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration","volume":"355","author":"Michels","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","article-title":"Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration","volume":"120","author":"Busbee","year":"2013","journal-title":"Ophthalmology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","article-title":"Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results","volume":"122","author":"Wykoff","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ophtha.2019.01.013","article-title":"Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study","volume":"126","author":"Kertes","year":"2019","journal-title":"Ophthalmology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"c2459","DOI":"10.1136\/bmj.c2459","article-title":"Bevacizumab for neovascular age related macular degeneration (ABC Trial): Multicentre randomised double masked study","volume":"340","author":"Tufail","year":"2010","journal-title":"BMJ"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","article-title":"Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial","volume":"138","author":"Khanani","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.ophtha.2007.04.030","article-title":"Angiographic and Optical Coherence Tomographic Results of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration","volume":"114","author":"Kaiser","year":"2007","journal-title":"Ophthalmology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","article-title":"Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration","volume":"121","author":"Ho","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","article-title":"Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study","volume":"125","author":"Silva","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1001\/jamaophthalmol.2019.5540","article-title":"Efficacy of a Treat-and-Extend Regimen with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: A Randomized Clinical Trial","volume":"138","author":"Kertes","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Brown, D.M., Jaffe, G.J., Wykoff, C.C., Adiguzel, E., Heier, J.S., and Khanani, A.M. (Ophthalmology, 2024). MERLIN: Two-Year Results of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid, Ophthalmology, online ahead of print.","DOI":"10.1016\/j.ophtha.2024.08.022"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrd3700","article-title":"Aflibercept\u00a0","volume":"11","author":"Stewart","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_101","unstructured":"Canadian Agency for Drugs and Technologies in Health (2020). Brolucizumab (Beovu): (Novartis Pharmaceuticals Canada Inc.): Indication: Treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD)."},{"key":"ref_102","unstructured":"Canadian Agency for Drugs and Technologies in Health (2022). Faricimab (Vabysmo): CADTH Reimbursement Recommendation: Indication: For the Treatment of Diabetic Macular Edema."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2147\/OPTH.S33372","article-title":"Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: Focus on aflibercept","volume":"6","author":"Stewart","year":"2012","journal-title":"Clin. Ophthalmol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2147\/DDDT.S40215","article-title":"Aflibercept in wet AMD: Specific role and optimal use","volume":"7","author":"Semeraro","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1522.e1","DOI":"10.1016\/j.ophtha.2006.05.055","article-title":"A Phase I Trial of an IV-Administered Vascular Endothelial Growth Factor Trap for Treatment in Patients with Choroidal Neovascularization due to Age-Related Macular Degeneration","volume":"113","author":"Nguyen","year":"2006","journal-title":"Ophthalmology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.ophtha.2009.04.030","article-title":"A Phase I Study of Intravitreal Vascular Endothelial Growth Factor Trap-Eye in Patients with Neovascular Age-Related Macular Degeneration","volume":"116","author":"Nguyen","year":"2009","journal-title":"Ophthalmology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: A VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.ophtha.2006.05.070","article-title":"Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration: Twenty-Four\u2013Week Results of an Uncontrolled Open-Label Clinical Study","volume":"113","author":"Moshfeghi","year":"2006","journal-title":"Ophthalmology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"6004047","DOI":"10.1155\/2022\/6004047","article-title":"Efficacy and Safety of Antivascular Endothelial Growth Factor (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Meta-analysis","volume":"2022","author":"Yin","year":"2022","journal-title":"J. Immunol. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"development of ranibizumab, an anti\u2013vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"\u015apiewak, D., Drzyzga, \u0141., Dorecka, M., and Wygl\u0119dowska-Promie\u0144ska, D. (2024). Summary of the Therapeutic Options for Patients with Dry and Neovascular AMD. J. Clin. Med., 13.","DOI":"10.3390\/jcm13144227"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11845-022-02929-8","article-title":"Literature review and proposal of best practice for ophthalmologists: Monitoring of patients following intravitreal brolucizumab therapy","volume":"192","author":"Kilmartin","year":"2023","journal-title":"Ir. J. Med. Sci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Moon, B.-H., Kim, Y., and Kim, S.-Y. (2023). Twenty Years of Anti-Vascular Endothelial Growth Factor Therapeutics in Neovascular Age-Related Macular Degeneration Treatment. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241613004"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Ferro Desideri, L., Traverso, C.E., Nicol\u00f2, M., and Munk, M.R. (2023). Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15051413"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.2147\/OPTH.S231801","article-title":"Angiopoietins as Potential Targets in Management of Retinal Disease","volume":"15","author":"Khanani","year":"2021","journal-title":"Clin. Ophthalmol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamaophthalmol.2020.2685","article-title":"Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial","volume":"138","author":"Sahni","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Tan, T.-E., and Wong, T.Y. (2023). Diabetic retinopathy: Looking forward to 2030. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1077669"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2337\/dc13-2002","article-title":"Ocular Anti-VEGF therapy for diabetic retinopathy: The role of VEGF in the pathogenesis of diabetic retinopathy","volume":"37","author":"Sundstrom","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3390\/diabetology3010011","article-title":"Diabetic Retinopathy: An Overview on Mechanisms, Pathophysiology and Pharmacotherapy","volume":"3","author":"Ansari","year":"2022","journal-title":"Diabetology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11892-021-01403-6","article-title":"Laser Therapy in the Treatment of Diabetic Retinopathy and Diabetic Macular Edema","volume":"21","author":"Everett","year":"2021","journal-title":"Curr. Diabetes Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders","volume":"331","author":"Thieme","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40123-017-0083-9","article-title":"A Review of Ranibizumab for the Treatment of Diabetic Retinopathy","volume":"6","author":"Stewart","year":"2017","journal-title":"Ophthalmol. Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema","volume":"372","author":"Wells","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Bahr, T.A., and Bakri, S.J. (2023). Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy. Life, 13.","DOI":"10.3390\/life13051098"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ajo.2023.07.012","article-title":"KESTREL and KITE Phase 3 Studies: 100-Week Results with Brolucizumab in Patients With Diabetic Macular Edema","volume":"260","author":"Wykoff","year":"2024","journal-title":"Am. J. Ophthalmol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","article-title":"KESTREL and KITE: 52-Week Results from Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema","volume":"238","author":"Brown","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial","volume":"126","author":"Sahni","year":"2019","journal-title":"Ophthalmology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): Two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","article-title":"Faricimab: First Approval","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Wang, B., Zhang, X., Chen, H., Koh, A., Zhao, C., and Chen, Y. (2022). A Review of Intraocular Biomolecules in Retinal Vein Occlusion: Toward Potential Biomarkers for Companion Diagnostics. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.859951"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Zhang, W., Liu, Y., and Sang, A. (2022). Efficacy and effectiveness of anti-VEGF or steroids monotherapy versus combination treatment for macular edema secondary to retinal vein occlusion: A systematic review and meta-analysis. BMC Ophthalmol., 22.","DOI":"10.1186\/s12886-022-02682-7"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.ophtha.2012.05.017","article-title":"Improved Vision-Related Function after Ranibizumab for Macular Edema after Retinal Vein Occlusion: Results from the BRAVO and CRUISE Trials","volume":"119","author":"Varma","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","article-title":"Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: Two-year results from the COPERNICUS study","volume":"121","author":"Heier","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","article-title":"Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study","volume":"123","author":"Clark","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ophtha.2014.09.024","article-title":"Improvement in vision-related function with intravitreal aflibercept: Data from phase 3 studies in wet age-related macular degeneration","volume":"122","author":"Yuzawa","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3928\/1542-8877-20050701-15","article-title":"Optical Coherence Tomography Findings After an Intravitreal Injection of Bevacizumab (Avastin\u00ae) for Macular Edema from Central Retinal Vein Occlusion","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg. Lasers Imaging Retin."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of prematurity","volume":"382","author":"Smith","year":"2013","journal-title":"Lancet"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Raghuveer, T.S., Zackula, R.E., and Hartnett, M.E. (J. Perinatol., 2024). Aflibercept to treat retinopathy of prematurity: Need for more research, J. Perinatol., online ahead of print.","DOI":"10.1038\/s41372-024-01997-1"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e20183061","DOI":"10.1542\/peds.2018-3061","article-title":"Screening Examination of Premature Infants for Retinopathy of Prematurity","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jama.2022.10564","article-title":"Effect of Intravitreal Aflibercept vs. Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial","volume":"328","author":"Stahl","year":"2022","journal-title":"JAMA"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): An open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ophtha.2022.05.019","article-title":"Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes","volume":"129","author":"Freedman","year":"2022","journal-title":"Ophthalmology"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity","volume":"364","author":"Kennedy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","article-title":"Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study","volume":"135","author":"Wallace","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology","volume":"124","author":"VanderVeen","year":"2017","journal-title":"Ophthalmology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of Bevacizumab and Its Effects on Serum VEGF and IGF-1 in Infants with Retinopathy of Prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.clp.2014.08.011","article-title":"Vascular Endothelial Growth Factor Antagonist Therapy for Retinopathy of Prematurity","volume":"41","author":"Hartnett","year":"2014","journal-title":"Clin. Perinatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature","volume":"27","author":"Nguyen","year":"2013","journal-title":"Eye"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jamaophthalmol.2018.3939","article-title":"Association of Acute Endophthalmitis with Intravitreal Injections of Corticosteroids or Anti\u2013Vascular Growth Factor Agents in a Nationwide Study in France","volume":"136","author":"Baudin","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","article-title":"Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease","volume":"56","author":"Tolentino","year":"2011","journal-title":"Surv. Ophthalmol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/IAE.0b013e31819a5f98","article-title":"Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: Our Experience After 2,000 Injections","volume":"29","author":"Ladas","year":"2009","journal-title":"Retina"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","article-title":"Twelve-month safety of intravitreal injections of bevacizumab (Avastin\u00ae): Results of the Pan-American Collaborative Retina Study Group (PACORES)","volume":"246","author":"Wu","year":"2008","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of Intravitreal Bevacizumab (Avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.preteyeres.2009.11.003","article-title":"The pivotal role of the complement system in aging and age-related macular degeneration: Hypothesis re-visited","volume":"29","author":"Anderson","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nri3459","article-title":"Immunology of age-related macular degeneration","volume":"13","author":"Ambati","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","article-title":"Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials","volume":"136","author":"Holz","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/IAE.0b013e3182979ddd","article-title":"A Phase ia dose-escalation study of the anti-factor d monoclonal antibody fragment fcfd4514s in patients with geographic atrophy","volume":"34","author":"Do","year":"2014","journal-title":"Retina"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"eaaf1443","DOI":"10.1126\/scitranslmed.aaf1443","article-title":"Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration","volume":"9","author":"Yaspan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): Two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1634\/theoncologist.2008-0086","article-title":"FDA Report: Eculizumab (Soliris\u00ae) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria","volume":"13","author":"Dmytrijuk","year":"2008","journal-title":"Oncologist"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e003573","DOI":"10.1136\/bmjopen-2013-003573","article-title":"A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)","volume":"3","author":"Rathbone","year":"2013","journal-title":"BMJ Open"},{"key":"ref_168","first-page":"1236","article-title":"Local Anti-C5 Therapy Suppresses Experimental Choroidal Neovascularization Through Reduction of Macrophage Infiltrate","volume":"53","author":"Liu","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ophtha.2013.09.044","article-title":"Systemic Complement Inhibition with Eculizumab for Geographic Atrophy in Age-Related Macular Degeneration: The COMPLETE Study","volume":"121","author":"Yehoshua","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"100290","DOI":"10.1016\/j.xops.2023.100290","article-title":"Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma","volume":"3","author":"Sun","year":"2023","journal-title":"Ophthalmol. Sci."},{"key":"ref_171","first-page":"1214","article-title":"Inhibition of complement C3 in geographic atrophy with NGM621: Phase 1 study results","volume":"62","author":"Eichenbaum","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_172","first-page":"2791","article-title":"Protection Against Vision Loss by ANX007: Results from the Phase 2 ARCHER Clinical Trial","volume":"65","author":"Boyer","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_173","unstructured":"Wykoff, C. (2022, January 3\u20134). The results of the CATALINA phase 2 study of NGM621 for geographic atrophy secondary to AMD. Proceedings of the Retina Society Annual Meeting, Pasadena, CA, USA."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ophtha.2013.10.037","article-title":"Cost-Effectiveness of Bevacizumab and Ranibizumab for Newly Diagnosed Neovascular Macular Degeneration","volume":"121","author":"Stein","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1136\/bjophthalmol-2018-312756","article-title":"Adalimumab for non-infectiousnoninfectious uveitis: Is it cost-effective?","volume":"103","author":"Bermejo","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"ref_176","first-page":"3","article-title":"Biosimilar Cost Savings in the United States: Initial Experience and Future Potential","volume":"7","author":"Mulcahy","year":"2018","journal-title":"Rand Health Q"}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/13\/4\/86\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:11:19Z","timestamp":1760112679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/13\/4\/86"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":176,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["antib13040086"],"URL":"https:\/\/doi.org\/10.3390\/antib13040086","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]}}}